Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis

Cholangiocarcinoma (CCA) complicates primary sclerosing cholangitis (PSC) in 10%‐20% of cases, but current tools for prediction of a CCA diagnosis are inadequate. Recently, we demonstrated the utility of the enhanced liver fibrosis (ELF) test to stratify prognosis in PSC. We observed that patients with PSC + CCA had significantly higher ELF score than those with PSC alone. In this study, we aimed to investigate further this association in a larger cohort of PSC patients with CCA compared with patients with PSC or CCA alone.

[1]  T. Karlsen,et al.  Primary sclerosing cholangitis - a comprehensive review. , 2017, Journal of hepatology.

[2]  T. Karlsen,et al.  Enhanced liver fibrosis test predicts transplant‐free survival in primary sclerosing cholangitis, a multi‐centre study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  K. Lindor,et al.  An update on cancer risk and surveillance in primary sclerosing cholangitis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[4]  F. Lund-Johansen,et al.  Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. , 2017, Journal of hepatology.

[5]  R. Zenouzi,et al.  Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance , 2017, Current opinion in gastroenterology.

[6]  B. Blechacz.  Cholangiocarcinoma: Current Knowledge and New Developments , 2016, Gut and liver.

[7]  T. Nijsten,et al.  Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross‐sectional comparison with procollagen‐3 N‐terminal peptide (P3NP) , 2016, The British journal of dermatology.

[8]  G. Gores,et al.  Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  F. Lund-Johansen,et al.  Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis , 2015, Hepatology.

[10]  P. O’Rourke,et al.  ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  D. Brenner,et al.  Aging and liver disease. , 2015, Current opinion in gastroenterology.

[12]  A. Bergquist,et al.  Epidemiology of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[13]  T. Karlsen,et al.  Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  G. Gores,et al.  Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting , 2014, Hepatology.

[15]  T. Pawlik,et al.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.

[16]  F. Vleggaar,et al.  Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis , 2013, Hepatology.

[17]  G. Gores,et al.  Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.

[18]  G. Petris,et al.  European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[19]  G. Gores,et al.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.

[20]  T. Karlsen,et al.  Update on primary sclerosing cholangitis. , 2013, Journal of hepatology.

[21]  Korbinian Brand,et al.  The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.

[22]  T. Karlsen,et al.  Primary sclerosing cholangitis , 2001, The Lancet.

[23]  C. Lees,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.

[24]  M. Manos,et al.  Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C , 2011, Journal of viral hepatitis.

[25]  Jing Xu,et al.  Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. , 2010, World journal of hepatology.

[26]  A. Torrice,et al.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. , 2010, World journal of gastrointestinal oncology.

[27]  Chung-Yi Li,et al.  Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications , 2010, Hepatology.

[28]  G. Gores,et al.  Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.

[29]  J. Everhart,et al.  Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. , 2009, Gastroenterology.

[30]  F. Lammert,et al.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.

[31]  A. West,et al.  Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay , 2008, Hepatology.

[32]  I. Endo,et al.  Intrahepatic cholangiocarcinoma , 2014, Radiopaedia.org.

[33]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[34]  W. Chai,et al.  Elevate Level of Glycosaminoglycans and Altered Sulfation Pattern of Chondroitin Sulfate Are Associated with Differentiation Status and Histological Type of Human Primary Hepatic Carcinoma , 2008, Oncology.

[35]  M. Manns,et al.  Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study , 2005, The American Journal of Gastroenterology.

[36]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[37]  T. Patel,et al.  Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.

[38]  W. Jarnagin,et al.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. , 2001, Journal of the American College of Surgeons.

[39]  T. Therneau,et al.  A revised natural history model for primary sclerosing cholangitis. , 1997, Mayo Clinic proceedings.

[40]  M. Tsuneyoshi,et al.  The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth. , 1999, The American journal of surgical pathology.